Use of Campath for Induction and Maintenance Therapy in Pancreas After Kidney Transplantation

Stopped early · Phase 4

Conditions studied: Diabetes Mellitus

In brief

This is a single center, prospective, open-label, randomized trial at the University of Minnesota Medical Center,Fairview. Primary objectives are to determine if rejection episodes and loss rates, graft survival, level of renal graft function, and patient survival rates with a Campath/MMF-based (Group 1) immunosuppressive protocol are lower than, or equal to, our protocol using thymoglobulin, tacrolimus, and MMF (Group 2). This study will investigate the first protocol that is both steroid-free and calcineurin inhibitor-free in pancreas after kidney transplant recipients.

Key facts

Study ID
NCT00177138
Run by
University of Minnesota
People needed
9
Starts
2004-07-01
Expected to finish
2006-11-01
Last updated by the study team
2013-02-07

Who can join

Age: 18 and older, up to 60. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.